Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric L Simpson

Showing results (131-140 of 315) with videos related to

Pageof 32
Sort By:
Lancet (London, England)|December 12, 2022
An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b studyEmma Guttman-Yassky, Eric L Simpson, Kristian Reich, et al.
American Journal of Clinical Dermatology|April 7, 2021
Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical TrialsBrett King, Catherine Maari, Edward Lain, et al.
The British Journal of Dermatology|April 30, 2023
Dupilumab improves patient-reported symptoms and health-related quality of life in children aged 6-11 years with severe atopic dermatitisCarsten Flohr, Alan D Irvine, Michael J Cork, et al.
Dermatology and Therapy|October 23, 2018
Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their FamiliesEric L Simpson, Amy S Paller, Mark Boguniewicz, et al.
Dermatology and Therapy|February 2, 2020
Qualitative Assessment of Adult Patients' Perception of Atopic Dermatitis Using Natural Language Processing Analysis in a Cross-Sectional StudyBruno Falissard, Eric L Simpson, Emma Guttman-Yassky, et al.
Journal of the American Academy of Dermatology|June 7, 2020
Dupilumab reduces absenteeism in patients with moderate to severe atopic dermatitis: Pooled results from the LIBERTY AD SOLO clinical trialsMarjolein de Bruin-Weller, Eric L Simpson, Michael Cork, et al.
Dermatology and Therapy|November 30, 2021
Clinical Tailoring of Baricitinib 2 mg in Atopic Dermatitis: Baseline Body Surface Area and Rapid Onset of Action Identifies Response at Week 16Jonathan I Silverberg, Mark Boguniewicz, Jill Waibel, et al.
Dermatology and Therapy|March 6, 2020
Correction to: Qualitative Assessment of Adult Patients' Perception of Atopic Dermatitis Using Natural Language Processing Analysis in a Cross-Sectional StudyBruno Falissard, Eric L Simpson, Emma Guttman-Yassky, et al.
Journal of the American Academy of Dermatology|July 18, 2018
Response to "Comment on: 'When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council'"Eric L Simpson, Nick J Reynolds, Carsten Flohr, et al.
The Journal of Dermatological Treatment|June 28, 2021
Improvement in sleep and itch and enhanced quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a phase 3 trial of baricitinib therapyPeter A Lio, Eric L Simpson, George Han, et al.
Pageof 32

Showing results (131-140 of 315) with videos related to

Sort By:
Pageof 32
Lancet (London, England)|December 12, 2022
An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b studyEmma Guttman-Yassky, Eric L Simpson, Kristian Reich, et al.
American Journal of Clinical Dermatology|April 7, 2021
Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical TrialsBrett King, Catherine Maari, Edward Lain, et al.
The British Journal of Dermatology|April 30, 2023
Dupilumab improves patient-reported symptoms and health-related quality of life in children aged 6-11 years with severe atopic dermatitisCarsten Flohr, Alan D Irvine, Michael J Cork, et al.
Dermatology and Therapy|October 23, 2018
Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their FamiliesEric L Simpson, Amy S Paller, Mark Boguniewicz, et al.
Dermatology and Therapy|February 2, 2020
Qualitative Assessment of Adult Patients' Perception of Atopic Dermatitis Using Natural Language Processing Analysis in a Cross-Sectional StudyBruno Falissard, Eric L Simpson, Emma Guttman-Yassky, et al.
Journal of the American Academy of Dermatology|June 7, 2020
Dupilumab reduces absenteeism in patients with moderate to severe atopic dermatitis: Pooled results from the LIBERTY AD SOLO clinical trialsMarjolein de Bruin-Weller, Eric L Simpson, Michael Cork, et al.
Dermatology and Therapy|November 30, 2021
Clinical Tailoring of Baricitinib 2 mg in Atopic Dermatitis: Baseline Body Surface Area and Rapid Onset of Action Identifies Response at Week 16Jonathan I Silverberg, Mark Boguniewicz, Jill Waibel, et al.
Dermatology and Therapy|March 6, 2020
Correction to: Qualitative Assessment of Adult Patients' Perception of Atopic Dermatitis Using Natural Language Processing Analysis in a Cross-Sectional StudyBruno Falissard, Eric L Simpson, Emma Guttman-Yassky, et al.
Journal of the American Academy of Dermatology|July 18, 2018
Response to "Comment on: 'When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council'"Eric L Simpson, Nick J Reynolds, Carsten Flohr, et al.
The Journal of Dermatological Treatment|June 28, 2021
Improvement in sleep and itch and enhanced quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a phase 3 trial of baricitinib therapyPeter A Lio, Eric L Simpson, George Han, et al.
Pageof 32